Fate Therapeutics Announces Five Presentations on Off-the-Shelf CAR T-cell Product Platform at ASGCT Annual Meeting
MWN-AI** Summary
Fate Therapeutics, Inc. (NASDAQ: FATE), a clinical-stage biopharmaceutical firm focused on innovative cellular immunotherapies derived from induced pluripotent stem cells (iPSCs), has announced key presentations at the American Society of Gene and Cell Therapy (ASGCT) 28th Annual Meeting, set to take place in New Orleans from May 13-17, 2025. Notably, Fate will present data on its Phase 1 clinical trial of FT522, an off-the-shelf CAR NK cell product targeting CD19 for treating relapsed/refractory B-cell lymphoma. FT522 incorporates unique Alloimmune Defense Receptor technology, which aims to eliminate the need for pre-therapy conditioning chemotherapy in patients.
The company will showcase a total of five presentations, including both oral and poster sessions, covering a range of applications of their novel iPSC technology in autoimmune disorders, hematological malignancies, and solid tumors. Key highlights include preclinical studies on strategies to enhance the functional persistence of allogeneic therapies and the development of next-generation CAR T-cell therapies that could potentially provide conditioning-free options for a diverse patient population.
Fate Therapeutics’ proprietary platform utilizes multiplex-engineered iPSCs to manufacture uniform, off-the-shelf cell products designed for broad therapeutic applications. With a strong intellectual property portfolio encompassing over 500 patents, the company aims to significantly advance the treatment landscape for both cancer and autoimmune diseases.
These advancements could position Fate Therapeutics as a leader in the field, propelling forward the potential of iPSC-derived therapies. More details, including presentation specifics, are available on the ASGCT's Annual Meeting website.
MWN-AI** Analysis
Fate Therapeutics (NASDAQ: FATE) has recently garnered attention ahead of the ASGCT Annual Meeting with the announcement of five presentations on their innovative off-the-shelf CAR T-cell platform. This news could potentially serve as a compelling opportunity for investors. The focus on their Phase 1 trial data for FT522, which boasts the promising Alloimmune Defense Receptor (ADR) technology, positions the company as a key player in revolutionizing treatment protocols that traditionally require chemotherapy conditioning.
Investors should note the significance of FT522, given its potential to mitigate the need for chemotherapy, thereby enhancing patient accessibility and treatment outcomes for relapsed/refractory B-cell lymphoma. The market response will likely hinge on the efficacy results presented at the meeting, particularly during the oral presentation on May 17. Positive results could drive a wave of investor interest, reflecting the collaborative potential of Fate’s iPSC product platform across various hematologic malignancies and autoimmune diseases.
Additionally, the timeliness of the presentations, along with the vast intellectual property backing the iPSC platform, signifies a robust pipeline that supports long-term growth. With over 500 issued patents, this extensive portfolio not only reinforces their competitive edge but also suggests a commitment to innovation in cell therapy.
However, investors should tread cautiously. The field of biopharmaceuticals is fraught with uncertainties, highlighted in Fate’s forward-looking statements regarding the possibility of trial delays and the unpredictable nature of clinical outcomes. Therefore, while the upcoming ASGCT meeting may present a lucrative investment opportunity, it is prudent for investors to weigh the potential risks involved in clinical development against the innovative promise that Fate Therapeutics holds in the realm of immunotherapy. Monitoring post-presentation market trends will be crucial for informed decision-making.
**MWN-AI Summary and Analysis is based on asking OpenAI to summarize and analyze this news release.
SAN DIEGO, April 29, 2025 (GLOBE NEWSWIRE) -- Fate Therapeutics, Inc. (NASDAQ: FATE), a clinical-stage biopharmaceutical company dedicated to bringing a first-in-class pipeline of induced pluripotent stem cell (iPSC)-derived cellular immunotherapies to patients, today announced that five presentations of clinical and preclinical data from the Company’s induced pluripotent stem cell (iPSC) product platform will be featured at the American Society of Gene and Cell Therapy (ASGCT) 28 th Annual Meeting, being held in New Orleans, Louisiana on May 13-17, 2025.
The Company has been selected to deliver an oral presentation on the translational data from its Phase 1 clinical trial of FT522, an off-the-shelf, CD19-targeted CAR NK cell product candidate, in patients with relapsed / refractory B-cell lymphoma (BCL) (NCT05950334). FT522 is the first product candidate to incorporate Alloimmune Defense Receptor (ADR) technology, which is designed to reduce or eliminate the need for administration of conditioning chemotherapy to patients receiving cell therapies. In addition, the Company will highlight preclinical data from its off-the-shelf, iPSC-derived, CAR T-cell product platform across autoimmune disease, hematological malignancy and solid tumor indications.
Accepted abstracts are available on the ASGCT Annual Meeting website . Presentation details are as follows:
Oral Presentation
Phase 1 Translational Assessment of an Off-The-Shelf CAR NK Cell Armed with Alloimmune Defense Technology for Conditioning-free Therapy
Session: Innovation in Alternative Cell Therapy Sources
Location: Room 391-392
Presentation Date / Time: Saturday, May 17, 2025, 11:00 AM CT
Poster Presentations
Alloimmune Defense Receptor Combined with Genetic Ablation of Adhesion Ligand CD58 is a Comprehensive Approach to Promote Functional Persistence of Allogeneic Cell Therapies without Conditioning Chemotherapy
Poster Number: 758
Presentation Date / Time: Tuesday, May 13, 2025, 6:00 PM CT
Targeting UPAR With Multiplexed-Engineered iPSC-Derived CAR T Cells to Reverse Age- and Insult-Related Fibrotic Disease
Poster Number: 789
Presentation Date / Time: Tuesday, May 13, 2025, 6:00 PM CT
Next-Generation Off-the-Shelf CAR T-Cell Therapies for Conditioning-Free Treatment of a Broad Spectrum of Autoimmune Diseases and Hematologic Malignancies
Poster Number: 1259
Presentation Date / Time: Wednesday, May 14, 2025, 5:30 PM CT
FT836, a Novel MICA/B-targeting CAR T-cell Therapy Engineered to Eliminate the Need for Conditioning Chemotherapy with Broad Activity Across Solid Tumor Indications
Poster Number: 1229
Presentation Date / Time: Wednesday, May 14, 2025, 5:30 PM CT
About Fate Therapeutics’ iPSC Product Platform
Human induced pluripotent stem cells (iPSCs) possess the unique dual properties of unlimited self-renewal and differentiation potential into all cell types of the body. The Company’s proprietary iPSC product platform combines multiplexed-engineering of human iPSCs with single-cell selection to create clonal master iPSC lines. Analogous to master cell lines used to mass produce biopharmaceutical drug products such as monoclonal antibodies, the Company utilizes its clonal master iPSC lines as a starting cell source to manufacture engineered cell products which are well-defined and uniform in composition, can be stored in inventory for off-the-shelf availability, can be administered in combination with other therapies, and can potentially reach a broad patient population. As a result, the Company’s platform is uniquely designed to overcome numerous limitations associated with patient- and donor-sourced cell therapies. Fate Therapeutics’ iPSC product platform is supported by an intellectual property portfolio of over 500 issued patents and 500 pending patent applications.
About Fate Therapeutics, Inc.
Fate Therapeutics is a clinical-stage biopharmaceutical company dedicated to bringing a first-in-class pipeline of induced pluripotent stem cell (iPSC)-derived cellular immunotherapies to patients with cancer and autoimmune diseases. Using its proprietary iPSC product platform, the Company has established a leadership position in creating multiplexed-engineered master iPSC lines and in the manufacture and clinical development of off-the-shelf, iPSC-derived cell products. The Company’s pipeline includes iPSC-derived natural killer (NK) cell and T-cell product candidates, which are selectively designed, incorporate novel synthetic controls of cell function, and are intended to deliver multiple therapeutic mechanisms to patients. Fate Therapeutics is headquartered in San Diego, CA. For more information, please visit www.fatetherapeutics.com .
Forward-Looking Statements
This release contains "forward-looking statements" within the meaning of the Private Securities Litigation Reform Act of 1995 including statements regarding the advancement of and plans related to the Company's product candidates, clinical studies and preclinical research and development programs, the Company’s progress, plans and timelines for the clinical investigation of its product candidates, including the initiation and continuation of enrollment in the Company’s clinical trials, the timing and availability of data from the Company’s clinical trials, the therapeutic and market potential of the Company’s research and development programs and product candidates, and the potential capabilities and benefits of the Company’s iPSC product platform. These and any other forward-looking statements in this release are based on management's current expectations of future events and are subject to a number of risks and uncertainties that could cause actual results to differ materially and adversely from those set forth in or implied by such forward-looking statements. These risks and uncertainties include, but are not limited to, the risk that the Company’s research and development programs and product candidates, including those product candidates in clinical investigation, may not demonstrate the requisite safety, efficacy, or other attributes to warrant further development or to achieve regulatory approval, the risk that results observed in prior studies of the Company’s product candidates, including preclinical studies and clinical trials, will not be observed in ongoing or future studies involving these product candidates, the risk of a delay or difficulties in the manufacturing of the Company’s product candidates or in the initiation and conduct of, or enrollment of patients in, any clinical trials, the risk that the Company may cease or delay preclinical or clinical development of any of its product candidates for a variety of reasons (including requirements that may be imposed by regulatory authorities on the initiation or conduct of clinical trials, changes in the therapeutic, regulatory, or competitive landscape for which the Company’s product candidates are being developed, the amount and type of data to be generated or otherwise to support regulatory approval, difficulties or delays in patient enrollment and continuation in the Company’s ongoing and planned clinical trials, difficulties in manufacturing or supplying the Company’s product candidates for clinical testing, failure to demonstrate that a product candidate has the requisite safety, efficacy, or other attributes to warrant further development, and any adverse events or other negative results that may be observed during preclinical or clinical development), and the risk that its product candidates may not produce therapeutic benefits or may cause other unanticipated adverse effects. For a discussion of other risks and uncertainties, and other important factors, any of which could cause the Company’s actual results to differ from those contained in the forward-looking statements, see the risks and uncertainties detailed in the Company’s periodic filings with the Securities and Exchange Commission, including but not limited to the Company’s most recently filed periodic report, and from time to time in the Company’s press releases and other investor communications. Fate Therapeutics is providing the information in this release as of this date and does not undertake any obligation to update any forward-looking statements contained in this release as a result of new information, future events or otherwise.
Contact:
Christina Tartaglia
Precision AQ
212.362.1200
christina.tartaglia@precisionaq.com
FAQ**
How does Fate Therapeutics Inc. (FATE) plan to differentiate its off-the-shelf CAR NK cell product FT522 from existing therapies in the treatment of relapsed/refractory B-cell lymphoma?
What key data is anticipated to be presented by Fate Therapeutics Inc. (FATE) at the ASGCT Annual Meeting regarding the efficacy of its iPSC-derived cellular immunotherapies?
Considering the risks mentioned, what steps is Fate Therapeutics Inc. (FATE) taking to address the potential delays in clinical trial enrollment for its product candidates?
How does the Alloimmune Defense Receptor technology developed by Fate Therapeutics Inc. (FATE) enhance the therapeutic potential of its cellular immunotherapy products?
**MWN-AI FAQ is based on asking OpenAI questions about Fate Therapeutics Inc. (NASDAQ: FATE).
NASDAQ: FATE
FATE Trading
-5.02% G/L:
$1.135 Last:
521,183 Volume:
$1.18 Open:
